3 results
Primary objective· • To investigate the safety and tolerability and establish either the dose of KU-0059436 which causes inhibition of PARP in combination with an active dose of carboplatin or the maximum tolerated dose (MTD) of KU-0059436 in…
Part IPrimary: • To evaluate safety and tolerability of ODM-111 in single oral escalating doses compared to placeboSecondary: • To evaluate pharmacokinetics (PK) and pharmacodynamic (PD) effects of ODM-111 after administration of single escalating…
Primary:•To compare the effect of venglustat with standard of care Fabry therapies on left ventricular mass index over 18 months in participants with Fabry disease and left ventricular hypertrophySecondary:•To evaluate the effect of venglustat on…